-
1.发明授权公开(公告)号：US08741352B2
公开(公告)日：2014-06-03
申请号：US11851923
申请日：2007-09-07
CPC分类号： A61K35/37 , A61K35/38 , A61K38/1825 , A61L27/227 , A61L27/3629 , A61L27/3633 , A61L27/3687 , A61K2300/00
摘要： Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.
摘要翻译： 描述了含有受控水平的生长因子如成纤维细胞生长因子-2（FGF-2）的包装的无菌医用移植物产品。 还描述了制造医疗移植产品的方法，其中控制和监测包括灭菌在内的处理以提供具有调节的已知水平的细胞外基质因子例如生长因子的医疗移植物产品，例如生长因子。 FGF-2。 优选的移植材料是从人或动物供体分离的细胞外基质材料，特别是含粘膜下层的细胞外基质材料。 进一步描述的是用于制备凝胶或可用于制备凝胶的ECM组合物，以及相关的制备和使用方法。
-
2.发明授权Graft materials containing bioactive substances, and methods for their manufacture 有权含有生物活性物质的接枝材料及其制造方法公开(公告)号：US08021692B2
公开(公告)日：2011-09-20
申请号：US10569218
申请日：2004-08-25
申请人： Michael C. Hiles , Jason P. Hodde , David M. J. Ernst , Lal Ninan
发明人： Michael C. Hiles , Jason P. Hodde , David M. J. Ernst , Lal Ninan
CPC分类号： A61L27/54 , A61K35/38 , A61K38/1825 , A61L27/227 , A61L27/24 , A61L27/3629 , A61L27/3633 , A61L27/3687 , A61L27/50 , A61L2300/414 , A61L2400/06
摘要： Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibrob-last Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.
摘要翻译： 描述了含有受控水平的生长因子如Fibrob-last Growth Factor-2（FGF-2）的包装的无菌医用移植物产品。 还描述了制造医疗移植产品的方法，其中控制和监测包括灭菌在内的处理以提供具有调节的已知水平的细胞外基质因子例如生长因子的医疗移植物产品，例如生长因子。 FGF-2。 优选的移植材料是从人或动物供体分离的细胞外基质材料，特别是含有细胞外基质材料的粘膜下层。 进一步描述的是用于制备凝胶或可用于制备凝胶的ECM组合物，以及相关的制备和使用方法。
-
3.发明申请公开(公告)号：US20100196480A1
公开(公告)日：2010-08-05
申请号：US12762058
申请日：2010-04-16
申请人： Michael C. Hiles , Jason P. Hodde , David M. J. Ernst , Lal Ninan
发明人： Michael C. Hiles , Jason P. Hodde , David M. J. Ernst , Lal Ninan
CPC分类号： A61L27/54 , A61K35/38 , A61K38/1825 , A61L27/227 , A61L27/24 , A61L27/3629 , A61L27/3633 , A61L27/3687 , A61L27/50 , A61L2300/414 , A61L2400/06
摘要： Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.
摘要翻译： 描述了含有受控水平的生长因子如成纤维细胞生长因子-2（FGF-2）的包装的无菌医用移植物产品。 还描述了制造医疗移植产品的方法，其中控制和监测包括灭菌在内的处理以提供具有调节的已知水平的细胞外基质因子例如生长因子的医疗移植物产品，例如生长因子。 FGF-2。 优选的移植材料是从人或动物供体分离的细胞外基质材料，特别是含粘膜下层的细胞外基质材料。 进一步描述的是用于制备凝胶或可用于制备凝胶的ECM组合物，以及相关的制备和使用方法。
-
4.发明授权Graft materials containing bioactive substances, and methods for their manufacture 有权含有生物活性物质的接枝材料及其制造方法公开(公告)号：US09504769B2
公开(公告)日：2016-11-29
申请号：US13225585
申请日：2011-09-06
申请人： Michael C. Hiles , Jason P. Hodde , David M. J. Ernst , Lal Ninan
发明人： Michael C. Hiles , Jason P. Hodde , David M. J. Ernst , Lal Ninan
CPC分类号： A61L27/54 , A61K35/38 , A61K38/1825 , A61L27/227 , A61L27/24 , A61L27/3629 , A61L27/3633 , A61L27/3687 , A61L27/50 , A61L2300/414 , A61L2400/06
摘要： Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.
摘要翻译： 描述了含有受控水平的生长因子如成纤维细胞生长因子-2（FGF-2）的包装的无菌医用移植物产品。 还描述了制造医疗移植产品的方法，其中控制和监测包括灭菌在内的处理以提供具有调节的已知水平的细胞外基质因子例如生长因子的医疗移植物产品，例如生长因子。 FGF-2。 优选的移植材料是从人或动物供体分离的细胞外基质材料，特别是含粘膜下层的细胞外基质材料。 进一步描述的是用于制备凝胶或可用于制备凝胶的ECM组合物，以及相关的制备和使用方法。
-
公开(公告)号：US08784889B2
公开(公告)日：2014-07-22
申请号：US11668908
申请日：2007-01-30
申请人： Jason P. Hodde , David M. J. Ernst
发明人： Jason P. Hodde , David M. J. Ernst
CPC分类号： A61L27/3687 , A61K35/22 , A61K35/38 , A61K35/42 , A61L27/3629 , A61L27/3633 , A61L27/3641
摘要： Described are devices, methods, and systems for grafting tissues or organs that are exposed to bacterial or mammalian enzymes that degrade collagenous materials. Illustrative medical grafts are processed by contacting a collagenous extracellular matrix (ECM) material with a mono-carboxylic acid having from four to about twelve carbon atoms, or mixtures of two or more such acids.
摘要翻译： 描述了用于移植暴露于降解胶原材料的细菌或哺乳动物酶的组织或器官的装置，方法和系统。 通过使胶原细胞外基质（ECM）材料与具有四至约十二个碳原子的单羧酸或两种或多种这些酸的混合物接触来处理说明性的医用移植物。
-
公开(公告)号：US09788821B2
公开(公告)日：2017-10-17
申请号：US12489199
申请日：2009-06-22
CPC分类号： A61B17/0057 , A61B2017/00004 , A61B2017/00641 , A61B2017/00654
摘要： Described are expanded collagenous materials and methods for their preparation and use. Certain expanded collagenous materials can be prepared by treating a first collagenous material with an alkaline substance under conditions effective to expand the first collagenous material, and recovering the expanded material. Expanded materials can exhibit beneficial persistence and tissue generation characteristics when implanted, and can be used in the formation of highly porous medical implant bodies which can be compressed to fractions of their original volume and will thereafter substantially recover their original volume.
-
7.发明授权Composite extracellular matrix materials and medical products formed therefrom 有权复合细胞外基质材料和由此形成的医疗产品公开(公告)号：US08741354B2
公开(公告)日：2014-06-03
申请号：US12488996
申请日：2009-06-22
申请人： Chad E. Johnson , David M. J. Ernst , Amy Overby
发明人： Chad E. Johnson , David M. J. Ernst , Amy Overby
CPC分类号： A61L27/56 , A61L27/3633
摘要： Described in certain aspects are composite extracellular matrix material products including expanded collagenous materials in combination with non-expanded collagenous materials. Methods for their preparation and use are also disclosed. Certain expanded collagenous materials can be prepared by treating a first collagenous material with an alkaline substance under conditions effective to expand the first collagenous material, and recovering the expanded material. Expanded materials can exhibit beneficial persistence and tissue generation characteristics when implanted, and can be used in the formation of highly porous medical implant bodies which can be compressed to fractions of their original volume and will thereafter substantially recover their original volume.
摘要翻译： 在某些方面描述的是复合细胞外基质材料产品，包括扩张的胶原材料与非扩张胶原材料的组合。 还公开了其制备和使用方法。 某些扩张的胶原材料可以通过在有效扩张第一胶原材料的条件下用碱性物质处理第一胶原材料并回收膨胀的材料来制备。 扩展的材料可以在植入时显示出有益的持续性和组织产生特性，并且可以用于形成高度多孔的医用植入物体，其可以被压缩成其原始体积的分数，然后将基本恢复其原始体积。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.032 秒)
